Trial Profile
Phase 1 Trial of 3-2,4 Dimethoxbenzylidene Anabaseine [GTS-21] in Schizophrenia
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 14 Jan 2020
Price :
$35
*
At a glance
- Drugs GTS 21 (Primary)
- Indications Schizophrenia
- Focus Therapeutic Use
- 30 Jun 2015 Status changed from recruiting to completed as per ClinicalTrials.gov record.
- 14 Nov 2013 Planned end date changed from 1 Sep 2009 to 1 Sep 2016 as reported by ClinicalTrials.gov.
- 02 Jul 2008 New trial record.